*Currently Accepting Participants*

*This page is for general information only. If you are interested in participating in this study, please refer to the PEAT recruitment flyer for more information.*

Study short name: PEAT

Study full name: A phase 2, dual-centre, randomised, controlled trial evaluating the effectiveness of probiotic and egg oral immunotherapy at inducing desensitisation or sustained unresponsiveness (remission) in participants with egg allergy compared with placebo (Probiotic Egg Allergen Oral Immunotherapy for Treatment of Egg Allergy: PEAT study).

Principle Investigator: Mimi Tang

Administering Institute: Murdoch Children’s Research Institute

Major funding source: National Health and Medical Research Council (NHMRC)

Study focus: Treatment

Study design: Intervention

Main study aim: The aim of the study is to test the hypothesis that probiotic and egg OIT is more effective than placebo at inducing sustained unresponsiveness (remission) in participants with egg allergy 8 weeks after end-of-treatment.

Additional study information: This is a randomised, placebo-controlled trial investigating whether probiotic given in combination with egg OIT is effective at inducing sustained unresponsiveness in egg allergic children.  

Study Population: The participants in this study are aged between 5 and 17 years old at time of enrolment. Participants are allergic to egg, and may have additional food allergies.

Study status: Currently recruiting participants with egg allergy, through September 2020.

Where can I find more information?

Study Recruitment Information: PEAT Recruitment Flyer

Australia New Zealand Clinical Trials Registry: https://www.australianclinicaltrials.gov.au/anzctr/trial/ACTRN12619000480189p

Study contact: [email protected]

Last modified: February 21st 2020 | Date created: August 20th 2019